2 research outputs found
Effect of low level laser therapy on tissue repair post teeth extraction in rats submitted to zoledronic acid and dexamethasone therapy
Submitted by Setor de Tratamento da Informa??o - BC/PUCRS ([email protected]) on 2016-08-11T14:06:57Z
No. of bitstreams: 1
DIS_RENATA_STIFELMAN_CAMILOTTI_PARCIAL.pdf: 1706843 bytes, checksum: 86f835b84ad4c9c1d525adc199226ade (MD5)Made available in DSpace on 2016-08-11T14:06:57Z (GMT). No. of bitstreams: 1
DIS_RENATA_STIFELMAN_CAMILOTTI_PARCIAL.pdf: 1706843 bytes, checksum: 86f835b84ad4c9c1d525adc199226ade (MD5)
Previous issue date: 2016-03-18Conselho Nacional de Pesquisa e Desenvolvimento Cient?fico e Tecnol?gico - CNPqCoordena??o de Aperfei?oamento de Pessoal de N?vel Superior - CAPESThe objectives of this study were: (a) elucidate whether Low Level Laser Therapy has positive effects in the treatment of bisphosphonate-related osteonecrosis of the jaw, by a systematic review of the literature. A systematic search of the PubMed, EMBASE, and Cochrane Library electronic databases was conducted, with no restrictions on language or year of publication. Search strategies were formulated using keywords and Boolean operators. The electronic search strategy retrieved 55 records. From 55 articles of wich 10 were ultimately included for data analysis in this review. Our findings show that treatment modalities including laser was associated with superior outcomes in terms of cure or improvement of bisphosphonate-related osteonecrosis of the jaw lesions as compared with conventional surgical and/or conservative drug therapy. It can be concluded that combined treatment with antibiotics, minimally invasive surgery (including Er:YAG laser surgery), and Low Level Laser Therapy in the early stages of the disease should be the gold standard for bisphosphonate-related osteonecrosis of the jaw management. (b) evaluate the influence of Low Level Laser Therapy in the 685nm and and 830nm wavelength (emission of red and infrared light repectivamente) in the healing process of the bone and soft tissues in rats under bisphosphonate therapy, zoledronic acid, and dexamethasone concomitantly underwent a surgery for extraction of upper molars. For this study were used twenty-eight Rattus norvegicus Wistar race, randomly divided into 4 groups of 7 animals each, one vehicle control group, a medication control group (administered Zoledronic Acid and dexamethasone) and other 2 groups wich were administered Zoledronic Acid and dexamethasone, one group was treatede with a laser with red light emission and the another onde with the and infrared light emission. There were statistically significant differences in the clinical evaluation of the wound and the weight of the animals. Regarding the histological evaluation, there were no statistically significant differences, although there are differences in the descriptions of the groups because it was possible to observe the difference maturation of the healing stage between groups. The effect of drug therapy with Zoledronic Acid and dexamethasone in the bone tissue repair process, induce osteonecrosis of the jaw in rats and slows down the healing process and we had positive influence on the bone and soft tissue repair process in the laser groups with red and infrared light emission at the stipulated dosimetry.Os objetivos deste estudo foram: (a) tentar elucidar, atrav?s de revis?o sistem?tica da literatura, se a laserterapia atua positivamente no tratamento da osteonecrose dos maxilares induzida por bisfosfonatos. Foi realizada uma busca sistem?tica das bases de dados eletr?nicas PubMed, Embase e Cochrane Library, sem restri??es de linguagem ou ano de publica??o. As estrat?gias de busca foram formuladas utilizando palavras-chave e operadores booleanos. A estrat?gia de busca eletr?nica encontrou 55 registros dos quais 10 foram finalmente inclu?dos para an?lise de dados nesta revis?o. Nossos resultados mostram que as modalidades de tratamento, incluindo o laser foi associado com resultados superiores em termos de cicatriza??o ou melhora de osteonecrose dos maxilares induzida por bisfosfonatos, em compara??o com a terapia com cir?rgica convencional e/ou conservadora com uso de medica??o. Pode-se concluir que o tratamento combinado com antibi?ticos, cirurgia minimamente invasiva (incluindo cirurgia a laser de Er: YAG), e a laserterapia de baixa pot?ncia nas fases iniciais da doen?a deve ser o padr?o ouro para osteonecrose dos maxilares induzida por bisfosfonatos; (b) avaliar a influ?ncia da laserterapia de baixa pot?ncia nos comprimendos de onda de 685nm e 830 nm (emiss?o de luz vermelha e infravermelha repectivamente) no processo de reparo dos tecidos ?sseo e mole em ratos sob terapia com bisfosfonato, no caso o ?cido Zoledr?nico, e Dexametasona concomitantemente submetidos a procedimento cir?rgico de exodontia dos molares superiores. Para essa pesquisa foram utilizados vinte e oito Rattus norvegicus da ra?a Wistar, aleatoriamente divididos em 4 grupos de 7 animais cada, sendo um grupo controle ve?culo, um grupo controle da medica??o (administrado ?cido Zoledr?nico e Dexametasona) e outros 2 grupos onde foram administrado ?cido Zoledr?nico e Dexametasona, sendo um grupo tratado com laser, com emiss?o de luz vermelha e outro, infravermelho. Houve diferen?as estatisticamente significativas na avalia??o cl?nica da ferida e no peso dos animais. Em rela??o ? avalia??o histol?gica, n?o houve diferen?as estatisticamente significativas, apesar de haver diferen?as nas descri??es entre os grupos, pois foi poss?vel observar a diferen?a de matura??o do est?gio de cicatriza??o entre os grupos. O efeito da terapia medicamentosa com o ?cido Zoledr?nico e Dexametasona concomitantes no processo de reparo dos tecidos ?sseo, induz a osteonecrose da maxila em ratos e retarda o processo de cicatriza??o e os efeitos da laserterapia com emiss?o de luz vermelha e infravermelha com a dosimetria estipulada teve influ?ncia positiva no processo de reparo de tecidos ?sseo e mole
Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi studyResearch in context
Summary: Background: Mucositis is a common and highly impactful side effect of conventional and emerging cancer therapy and thus the subject of intense investigation. Although common practice, mucositis assessment is heterogeneously adopted and poorly guided, impacting evidence synthesis and translation. The Multinational Association of Supportive Care in Cancer (MASCC) Mucositis Study Group (MSG) therefore aimed to establish expert recommendations for how existing mucositis assessment tools should be used, in clinical care and trials contexts, to improve the consistency of mucositis assessment. Methods: This study was conducted over two stages (January 2022–July 2023). The first phase involved a survey to MASCC-MSG members (January 2022–May 2022), capturing current practices, challenges and preferences. These then informed the second phase, in which a set of initial recommendations were prepared and refined using the Delphi method (February 2023–May 2023). Consensus was defined as agreement on a parameter by >80% of respondents. Findings: Seventy-two MASCC-MSG members completed the first phase of the study (37 females, 34 males, mainly oral care specialists). High variability was noted in the use of mucositis assessment tools, with a high reliance on clinician assessment compared to patient reported outcome measures (PROMs, 47% vs 3%, 37% used a combination). The World Health Organization (WHO) and Common Terminology Criteria for Adverse Events (CTCAE) scales were most commonly used to assess mucositis across multiple settings. Initial recommendations were reviewed by experienced MSG members and following two rounds of Delphi survey consensus was achieved in 91 of 100 recommendations. For example, in patients receiving chemotherapy, the recommended tool for clinician assessment in clinical practice is WHO for oral mucositis (89.5% consensus), and WHO or CTCAE for gastrointestinal mucositis (85.7% consensus). The recommended PROM in clinical trials is OMD/WQ for oral mucositis (93.3% consensus), and PRO-CTCAE for gastrointestinal mucositis (83.3% consensus). Interpretation: These new recommendations provide much needed guidance on mucositis assessment and may be applied in both clinical practice and research to streamline comparison and synthesis of global data sets, thus accelerating translation of new knowledge into clinical practice. Funding: No funding was received